Navigation Links
FirstMark to Exhibit at Cardiovascular Research Technologies (CRT) 2012 Conference
Date:2/1/2012

WASHINGTON and SAN DIEGO, Feb. 1, 2012 /PRNewswire-iReach/ -- FirstMark is pleased to announce that it will be exhibiting at the CRT 2012 Conference in Washington D.C. on February 5 – 7. FirstMark will showcase its new cardiovascular diagnostic test PREvent. PREvent is the first and only multiple biomarker blood test on the market that predicts near term (2-3 years) risk of myocardial infarction in patients with suspected or confirmed, insignificant or significant stable CAD. The test is a critical advancement in cardiovascular medicine addressing the unmet need to assess risk of near term MI.

"CRT 2012 is a great opportunity to showcase our new cardiovascular blood test. It also gives us the chance to meet with leading cardiologists from around the country and update them first-hand on our new test, including the very impressive final data. We are proud to be a part of such a key industry event," says Thomas Silberg, President and CEO of GenWay Biotech.

Details about the test's research will be given in an oral presentation at the conference, An Aggregate of 3 Biomarkers Predict Very High Risk of Acute Myocardial Infarction and Death, by Dr. Stephen E. Epstein, Director of the Vascular Biology Laboratory and Executive Director of the Cardiovascular Research Institute, MedStar Health Research Institute at the Washington Hospital Center, 11:35 a.m. Monday, February 6. (Atherosclerosis & HDL Therapy).  

About FirstMark PREvent

FirstMark PREvent is the first and only multiple biomarker blood test on the market that predicts near term (2-3 years) risk of myocardial infarction and/or death in patients with suspected or confirmed, insignificant or significant stable CAD. PREvent aggregates three cardiovascular biomarkers that identify the pathways that lead to vulnerable plaque formation. In a clinical study, an annual average of 18.2% of patients with all three biomarkers elevated experienced a myocardial infarction or  death, compared to only 2.45% of significant CAD patients with normal biomarker levels. In addition, the multiple biomarker model adds markedly to traditional risk-prediction by significantly improving C-statistics from 0.695 for base model to 0.750, distinguishing high risk subjects from low risk subjects. PREvent distinguishes the top 5% of CAD patients who are at a 5.5 times greater risk of a near term cardiac event, allowing physicians to identify individuals in urgent need of the most aggressive treatment, compliance and monitoring. FirstMark is a Division of GenWay Biotech.

About GenWay Biotech, Inc.

GenWay Biotech, Inc., is comprised of three divisions. The FirstMark division is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. GenWay's catalog products and custom services divisions are focused on protein and antibody solutions. GenWay's headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area. For additional information about GenWay Biotech, please visit GenWayBio.com or FirstMarkPREvent.com. 

Media Contact:

Deborah Moore GenWay Biotech, Inc., 858-458-0866, dmoore@genwaybio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE GenWay Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. 2011 ErgoExpo Attendees Choice Award Winners Announced During Sold Out Expo; Exhibitor Renewal for 2012 Hits 96% and Counting
2. At RSNA, DR Systems Will Exhibit RIS, Reporting, Peer Review Systems
3. ALTEN and Calsoft Labs at the BWF 2011 Exhibition
4. Selexis SA to Partner and Exhibit at BIO 2011 in Washington DC
5. China Botanic Exhibits All-Natural Products at the 65th PHARMACHINA Fair
6. VENENUM Biodesign to Exhibit at SBS
7. Sensus Healthcare Announces Its Exhibitor Attendance at the 9th Annual South Beach Symposiumâ„¢
8. Nanowires exhibit giant piezoelectricity
9. At RSNA, DR Systems Will Exhibit New Unity v-Series Web PACS
10. WAVE Conference and Exhibition 2011 Taking Products to Market incorporating Micro & Nano Technology
11. Graphene exhibits bizarre new behavior well suited to electronic devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: CO ) ... blood collection, laboratory testing, hematopoietic stem cell processing and ... results for the third quarter and first nine months ... Third Quarter of Fiscal 2017 Highlights ... increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ("China ... company in China, today announced its financial results for the ... Fourth Quarter 2016 Financial Highlights Total ... in RMB terms, or increased by 13.6% in USD terms ... of 2015. Gross profit increased by 13.3% ...
Breaking Biology Technology:
(Date:2/14/2017)... 14, 2017  Wake Forest Baptist Medical Center today ... chief executive officer (CEO). Freischlag joins the medical center ... McConnell , M.D., who last year announced that he ... Center, after leading it since 2008.   ... Wake Forest Baptist,s academic health system, which includes Wake ...
(Date:2/8/2017)... 8, 2017 About Voice Recognition Biometrics Voice ... it against a stored voiceprint template. Acoustic features ... and tone are compared to distinguish between individual ... as most PCs already have a microphone and ... recognition biometrics are most likely to be deployed ...
(Date:2/7/2017)... 2017   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the latest ... highly flexible and award winning eClinical solution, is now ... is a proven Software-as-a-Service (SaaS) clinical research technology ... but also delivers an entire suite of eClinical tools ...
Breaking Biology News(10 mins):